Related Experiment Video
Updated: Oct 2, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Integrated Analysis of circRNA-miRNA-mRNA ceRNA Network in Cardiac Hypertrophy
Yang-Hao Chen1, Ling-Feng Zhong1, Xia Hong2
1The Key Laboratory of Cardiovascular Disease of Wenzhou, Department of Cardiology, The First Affiliated Hospital of WenZhou Medical University, WenZhou, China.
Insights
This study identifies key circular RNAs (circRNAs) and their regulatory networks involved in cardiac hypertrophy, a heart condition. These findings offer new insights into the molecular mechanisms underlying this adaptive cardiac response.
Area of Science:
- Cardiology
- Molecular Biology
- Genomics
Background:
- Cardiac hypertrophy is an adaptive response to increased hemodynamic load.
- Abnormal non-coding RNA expression is increasingly linked to myocardial hypertrophy.
- Circular RNAs (circRNAs) are implicated in cardiac hypertrophy, but their regulatory networks are poorly understood.
Purpose of the Study:
- To systematically analyze circRNA-related competing endogenous RNA (ceRNA) regulatory networks in cardiac hypertrophy.
- To identify key circRNAs, messenger RNAs (mRNAs), and microRNAs (miRNAs) involved in this process.
Main Methods:
- Utilized public databases for prediction and screening of differentially expressed mRNAs and miRNAs.
- Constructed a circRNA-mediated ceRNA regulatory network.
- Validated key molecular targets using Polymerase Chain Reaction (PCR) in an animal model.
Main Results:
- Established the first circRNA-mediated ceRNA regulatory network for myocardial hypertrophy.
- Identified three key mRNAs (Col12a1, Thbs1, Tgfbr3).
- Identified four key miRNAs (miR-20a-5p, miR-27b-3p, miR-342-3p, miR-378a-3p).
- Identified four key circRNAs (circ_0002702, circ_0110609, circ_0013751, circ_0047959) potentially crucial for cardiac hypertrophy.
Conclusions:
- The study presents a novel circRNA-ceRNA network associated with cardiac hypertrophy.
- Specific circRNAs, mRNAs, and miRNAs identified may serve as critical regulators or therapeutic targets for cardiac hypertrophy.
Abstract:
Cardiac hypertrophy is an adaptive cardiac response that accommodates the variable hemodynamic demands of the human body during extended periods of preload or afterload increase. In recent years, an increasing number of studies have pointed to a potential connection between myocardial hypertrophy and abnormal expression of non-coding RNAs. Circular RNA (circRNA), as one of the non-coding RNAs, plays an essential role in cardiac hypertrophy. However, few studies have systematically analyzed circRNA-related competing endogenous RNA (ceRNA) regulatory networks associated with cardiac hypertrophy. Therefore, we used public databases from online prediction websites to predict and screen differentially expressed mRNAs and miRNAs and ultimately obtained circRNAs related to cardiac hypertrophy. Based on this result, we went on to establish a circRNAs-related ceRNA regulatory network. This study is the first to establish a circRNA-mediated ceRNA regulatory network associated with myocardial hypertrophy. To verify the results of our analysis, we used PCR to verify the differentially expressed mRNAs and miRNAs in animal myocardial hypertrophy model samples. Our findings suggest that three mRNAs (Col12a1, Thbs1, and Tgfbr3), four miRNAs (miR-20a-5p, miR-27b-3p, miR-342-3p, and miR-378a-3p), and four related circRNAs (circ_0002702, circ_0110609, circ_0013751, and circ_0047959) may play a key role in cardiac hypertrophy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

